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Abstract
Jak1/2 inhibition suppresses STAT3 phosphorylation that is characteristic of many cancers. Activated STAT3 promotes the
transcription of factors that enhance tumor growth, survival, and angiogenesis. AZD1480 is a novel small molecule inhibitor
of Jak1/2, which is a keymediator of STAT3 activation. This study examined the use of diffusion-weighted (DW) and dynamic
contrast-enhanced (DCE) magnetic resonance imaging (MRI) biomarkers in assessing early tumor response to AZD1480.
Cediranib (AZD2171), a vascular endothelial growth factor signaling inhibitor, was used as a comparator. Thirty mice were
injected with Calu-6 lung cancer cells and randomized into the three treatment groups: AZD1480, cediranib, and sham. DW-
MRI and DCE-MRI protocols were performed at baseline and at days 3 and 5 after treatment. The percent change from
baseline measurements for K trans, ADC, and ve were calculated and compared with hematoxylin and eosin (H&E), CD31,
cParp, and Ki-67 histology data. Decreases in K trans of 29% (P < .05) and 53% (P < .05) were observed at days 3 and 5,
respectively, for the cediranib group. No significant changes in K trans occurred for the AZD1480 group, but a significant
increase in ADC was demonstrated at days 3 (63%, P < .05) and 5 (49%, P < .05). CD31 staining indicated diminished
vasculature in the cediranib group, whereas significantly increased cParp staining for apoptotic activity and extracellular
space by image analysis of H&Ewere present in the AZD1480 group. These imaging biomarker changes, and corresponding
histopathology, support the use of ADC, but not K trans, as a pharmacodynamic biomarker of response to AZD1480 at these
time points.
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Introduction
Targeting signal transduction pathways has become a major strategy in
the development of novel cancer therapies. Inhibition of these pathways
can promote antiangiogenic, proapoptotic, and/or antiproliferative
effects [1]. An example of this type of targeted therapy is a novel class
of pharmaceuticals known as Jak inhibitors. The Janus family of kinases
(Jak) is fundamental to mediating activation of signal transducers and
activator of transcription (STAT) proteins. STAT proteins are respon-
sible for mediating cytokine and growth factor responses. During the
past two decades, it has been shown that persistent activation of STAT3
is found in a wide variety of human cancer cell lines [2] and that aber-
rant STAT3 activation is necessary for proliferation and survival of
some cancer cell lines [3,4].
In addition to these tumor cell–autonomous effects, it has been
reported that persistent activation of STAT3 directly targets vas-
cular endothelial growth factor (VEGF) [5], one of the most potent
angiogenesis-inducing signaling factors. STAT3 acts to direct tran-
scriptional activation of VEGF, as well as having downstream effects
that, when inhibited, may slow hypoxia-inducible factor 1 activation,
which is another upregulator of VEGF [6].
A Jak1/2 small molecule inhibitor, AZD1480, has been shown to
actively suppress the role of STAT3 in tumorigenesis. Hedvat et al.
[7] demonstrated that AZD1480 significantly reduced STAT3 phos-
phorylation in multiple tumor xenograft models that exhibit aberrant,
persistent STAT3 activation, and inhibited tumor xenograft growth.
In recent years, there has been considerable growth in the number
and capabilities of noninvasive imaging biomarkers of tumor micro-
environment and response to therapy. Diffusion-weighted magnetic
resonance imaging (DW-MRI) provides the ADC, which has been
shown to correlate with biophysical properties such as cell density,
whereas dynamic contrast-enhancedMRI (DCE-MRI) provides K trans,
a biomarker of tumor perfusion and microvascular permeability [8,9].
DCE-MRI also provides ve, a biomarker of the extravascular extra-
cellular space, although changes in this biomarker can be difficult to
interpret because the measurement is not always robust.
The microscopic thermally induced behavior of molecules moving
in a random pattern is referred to as self-diffusion or Brownian motion
[10]. In a system that is defined by small compartments, such as cells,
that are separated by semipermeable barriers, such as cell membranes,
the rate of self-diffusion is less than that of free diffusion and can be
described by an apparent diffusion coefficient (ADC), which depends
on the properties and spatial relationship between these barriers [11–
13], which act to restrict the free diffusion of water molecules. Tech-
niques such as a pulsed-gradient spin-echo (PGSE) sequence, which
are sensitive to this diffusion and the effects of restrictions on water
movements at spatial scales up to the order of several microns, have
been designed; this spatial scale is on the order of the diameter of a
cell and therefore can be used as an estimate of cellularity. In well-
controlled situations, the variations in ADC have been shown to corre-
late inversely with tissue cellularity [14] and have been used to monitor
treatment response in a variety of anticancer therapies, including both
cytotoxic and antivascular/antiangiogenic drugs [15–17].
A second technique that has been shown to be sensitive to changes
in physiological characteristics of tumor vasculature is DCE-MRI [8,18],
which characterizes the pharmacokinetics of an injected contrast agent
as it enters and exits a region of interest (ROI) or tissue of interest. By
acquiring T 1-weighted images of the MRI signal over time, the kinetics
of the CA can be quantified, and using a model to describe its distri-
bution, biologically relevant parameters can be extracted that represent
changes in, for example, blood flow, permeability, and tissue volume
fractions. These measurements have been used to diagnose cancer
and monitor treatment [8].
Two important processes regulated by STAT3 are cellular prolifera-
tion and tumor angiogenesis, so we investigated the value of DW-MRI
and DCE-MRI biomarkers for assessing the response to AZD1480, a
novel Jak1/2 inhibitor, compared with a potent antiangiogenic agent,
cediranib [19], at early treatment time points.
Materials and Methods
Tumor Model
Calu-6 human lung carcinoma cells were grown as described by
Wedge et al. [20]. Cediranib [19] and AZD1480 (unpublished) have
been shown to inhibit tumor growth in this cell line. Briefly, the cells
were grown in medium containing 10% fetal calf serum and 2 mM
L-glutamine in Eagle minimal essential medium with 1% sodium
pyruvate (100 mM) and 1% nonessential amino acids (Life Technol-
ogies, Inc, Grand Island, NY). Cells growing at 80% confluence were
harvested, and a single cell suspension containing 1 × 106 cells sus-
pended in 100 μl of medium was injected subcutaneously on the
flank. Tumors were grown for 15 to 20 days to reach a size of approx-
imately 200 to 250 mm3 before imaging.
Animal Model
Thirty adult female fox nu/nu (8-10 weeks of age) were purchased
from Charles River Laboratories (Raleigh, NC), housed in pathogen-
free facilities with a 12-hour light/dark cycle (6 A.M. to 6 P.M.), and
provided with rodent chow and tap water ad libitum. For DCE-
MRI studies, a 26-gauge jugular catheter was surgically implanted
to allow for delivery of the contrast agent. All animals were imaged
Table 1. Average Absolute K trans Values for Each Treatment Group.
Treatment Group Baseline (/min) Day 3 (/min) Day 5 (/min)
AZD1480 0.06 ± 0.03 (n = 8) 0.05 ± 0.05 (n = 8) 0.04 ± 0.01 (n = 5)
Cediranib 0.06 ± 0.02 (n = 7) 0.04 ± 0.02 (n = 7) 0.03 ± 0.02 (n = 6)
Sham 0.07 ± 0.03 (n = 6) 0.05 ± 0.02 (n = 5) 0.04 ± 0.02 (n = 6)
Values are presented as mean ± SD.
Table 2. Average Absolute ADC Values for Each Treatment Group.
Treatment Group Baseline (× 10−4 mm2/s) Day 3 (× 10−4 mm2/s) Day 5 (× 10−4 mm2/s)
AZD1480 6.00 ± 1.59 (n = 9) 7.33 ± 0.98 (n = 4) 8.59 ± 3.02 (n = 8)
Cediranib 6.51 ± 1.48 (n = 5) 6.86 ± 2.67 (n = 5) 8.60 ± 1.43 (n = 3)
Sham 6.81 ± 1.81 (n = 7) 6.53 ± 2.19 (n = 5) 5.00 ± 1.60 (n = 3)
Values are presented as mean ± SD.
Table 3. Average Absolute ve Values for Each Treatment Group.
Treatment Group Baseline (/min) Day 3 (/min) Day 5 (/min)
AZD1480 0.50 ± 0.27 (n = 8) 0.58 ± 0.21 (n = 8) 0.49 ± 0.29 (n = 5)
Cediranib 0.41 ± 0.15 (n = 7) 0.37 ± 0.14 (n = 7) 0.24 ± 0.07 (n = 6)
Sham 0.33 ± 0.12 (n = 6) 0.39 ± 0.15 (n = 5) 0.36 ± 0.10 (n = 6)
Values are presented as mean ± SD.
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at three time points: a baseline scan was acquired before any treat-
ment and then two subsequent sessions at days 3 and 5 after the
initiation of treatment. The mice were then humanely killed for histo-
logic analysis of tumor tissues. During all imaging procedures, the
mice were anesthetized using a 2%/98% isoflurane/oxygen mixture.
Body temperature was maintained through a flow of warm air through
the magnet bore, and temperature and respiratory rate were moni-
tored throughout the entire experiment. All procedures in the experi-
ment were reviewed and approved by our institutional animal care and
use committee.
Treatment
The vehicle for AZD1480 was prepared using 0.1 ml of Tween-80
(Sigma-Aldrich, St Louis, MO), 0.5 g of methylcellulose powder,
and 100 ml of distilled water stirred overnight. Vehicle was added
to a dose of 50 mg/kg of AZD1480 such that the administered vol-
ume was 10 ml/kg, and pH was adjusted to 2.0. The vehicle for
cediranib was prepared using 0.1 ml of Tween-80 added to 100 ml
of distilled water. Vehicle was added to a dose of 6 mg/kg such that
the administered volume was 10 ml/kg. All drugs and vehicles were
stored at 4°C. Thirty mice were randomly assigned to one of the
following three treatment groups once tumor volumes were ap-
proximately 200 mm3: 50 mg/kg AZD1480 per os daily for 6 days,
6 mg/kg, cediranib per os daily for 6 days, and vehicle control per os
daily for 6 days.
Data Acquisition
Diffusion-Weighted MRI. Animals were imaged on a 9.4-T MR
scanner (Varian, Palo Alto, CA) with a 38-mm quadrature coil (Varian)
at all three time points. Because of technical issues, three animals had
day 5 data and four animals had day 3 data acquired on a 7-T MR
scanner (Varian) using identical protocols. A gradient echo scout
sequence was used to locate the tumor tissue. Once the ROI was lo-
cated, 15 slices were imaged (1 mm thick, interleaved) with diffusion
weighting using a gated and navigated PGSE sequence. DW-MRI param-
eters were as follows: TR\TE\α = 2000 milliseconds\42 milliseconds\15°,
acquisitionmatrix = 1282, field of view (FOV) = 35mm2, and number of
excitations (NEX) = 2, with Δ = 35.00 milliseconds and δ = 5.00 milli-
seconds, giving b values of 150.88, 500.2, and 800.22 mm2/s.
Dynamic Contrast-Enhanced MRI. After DW-MRI, precontrast
T 1 maps were obtained using an inversion recovery snapshot fast low-
angle-shot gradient echo sequence with an adiabatic inversion pulse and
nine inversion times (TIs) ranging from 20 to 10,000 milliseconds. Im-
aging parameters were as follows: TR\TE\α = 12100 milliseconds\3.44
milliseconds\15° and NEX = 4, FOV = 35 mm2, and matrix = 1282.
The data were then fit to to obtain T 1 maps for all 15 slices of data.
The DCE-MRI protocol used a T 1-weighted, gradient echo sequence
to obtain 40 serial images for each of 15 axial planes in 18 minutes of
imaging. The parameters were as follows: TR\TE\α = 100 milliseconds\
2.83 milliseconds\25°, NEX = 2, with the same acquisition matrix
and FOV as for the T 1 map. A bolus of 0.1 mmol/kg gadopentetate
(Magnevist; Bayer Healthcare Pharmaceuticals, Inc, Wayne, NJ) was
delivered for 2.5 seconds with an automated Harvard pump (2.4 ml/min)
through a jugular catheter beginning after the acquisition of the fifth
dynamic image.
Figure 1. Volumetric data for all animals used in each treatment
group. The solid square/solid line represents the cediranib group,
whereas the open circle/dashed line represents the AZD1480. The
sham group is represented by the triangle/dashed line with the
vertical lines indicating the 95% confidence intervals for each time
point. There is no significant difference between any of the groups
at any time point (ncediranib = 12/nAZD1480 = 10/nsham = 9).
Figure 2. Example DCE-MRI curves from each treatment group. (A) Subject from the cediranib treatment group, with the black line
indicating the baseline, the red line indicating day 3 data, and the blue line representing day 5 data. As noted by the arrow, there is
dramatic decrease in K trans for the cediranib group. (B) ROI curves from the AZD1480 group, with the arrow showing that no specific
pattern in K trans can be detected. (C) Sham group showing little detectable change in K trans values.
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Data Analysis
Diffusion-Weighted MRI. For the PGSE sequence used, the
signal (S ) will change because of the diffusion and can be described as
S = S0 :eADC
:b; ½1
where b is diffusion weighting imparted by magnetic field gradients and
S0 is the signal without diffusion weighting. Changing the magnitude
or duration of the diffusion gradients, thus changing the b values, yields
multiple image sets with varying diffusion weighting. The data can then
be exponentially fit to acquire ADC values on a voxel-by-voxel basis.
The DW images acquired at three separate b values, 150.88, 500.2,
and 800.22 mm2/s, were fit to to extract the ADC values at every
ROI and voxel location.
Dynamic Contrast-Enhanced MRI. Data collected for the T 1
map were fit using a nonlinear least squares method in Matlab 2008a
(The MathWorks, Natick, MA). For each inversion pulse, eight lines
of k space were acquired; these eight lines account for a single effective
TI (TIeff), with the TIeff corresponding to the timing of the first col-
lected line. A centric phase encode table was used to reconstruct the
data, and no cardiac gating was used during the acquisition. Under
the assumption that TR T 1 and a sufficiently low flip angle, the signal
at each acquisition can be described in the following equation:
S = S0 :
 1 − m1:e−T Ieff =T1
 ; ½2
where m1 is a free parameter to account for a partial inversion and S0
and S are the signal intensities at equilibrium at the effective inversion
time (TIeff), respectively.
Once precontrast T 1 maps were calculated, tumor signal curves
were fit to a two-compartment model to extract pharmacokinetic
parameters [21]. Briefly, if we assume that a homogeneous distribu-
tion of CA exists in both compartments and there exists no back flux
to either compartment, then any of the previously mentioned cases
can be generalized into a linear, first-order ordinary differential equa-
tion describing CA kinetics into the tissue
d
dt
Ct tð Þ = K trans :Cp tð Þ − K trans=veð Þ :Ct tð Þ; ½3
where C t is the concentration in the tissue compartment, Cp is the
concentration in the plasma compartment, whereas K trans is the transfer
constant between Cp and C t and ve is the extravascular extracellular
volume fraction. The solution to is
CtðtÞ = K trans : ∫t0 CpðuÞ : e K
trans=veð ÞðtuÞdu: ½4
The signal time course from the tissue for each voxel was fit to using
a nonlinear least squares approach by incorporating 1) the initial
T 1 values [22], 2) the fast exchange limit model with relaxivity for
gadopentetate at 9.4 T = 4.8/mM/s (unpublished results) and a hemat-
ocrit value of 0.45, based on literature values [23], and 3) a population-
derived vascular input function or Cp(t) derived from a cohort of
10 fox nu/nu mice found using the identical protocol described
Loveless et al. [24].
Histology
On day 6 (1 day after the final imaging session), animals were
dosed and killed 2 hours later using CO2. Although the histologic
samples were collected 1 day after imaging, it was important to mimic
the imaging timeline; this ensured that the histology and molecular
markers would reflect 2 hours after dosing just as when imaging
was performed. The tumor tissue was excised, placed into tissue
cassettes, fixed in 10% formalin (Fisher, Pittsburgh, PA) for 24 to
48 hours, and stored in 70% ethanol. Samples were paraffin embed-
ded and sectioned at 5-μm thickness. Immunohistochemistry was
performed on the Ventana Discovery XT Autostainer. Samples were
stained for phosphorylated STAT3 (pSTAT3, CST9145; Cell Signal-
ing Technology, Danvers, MA), Ki-67 (180191Z; Invitrogen, Grand
Island, NY), cleaved Parp1 (cParp, 04-576; Millipore, Billerica, MA),
Figure 3. (A, B, and C) Percent change from baseline for K trans,
ADC, and ve, respectively, from a center slice ROI where cediranib
(▪), AZD1480 (○), and Sham (▴), whereas the 95% confidence in-tervals are represented by the vertical bars. *P < .05. Statistical
significance was found for K trans in the cediranib treatment group,
whereas AZD1480 days 3 and 5 data showed significant increases
in ADC. A significant decrease was found for ve in the cediranib
treatment group. See text for additional details.
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CD31 (sc1506; Santa Cruz Biotechnology, Santa Cruz, CA), and with
hematoxylin and eosin (H&E; Ventana, Tucson, AZ).
Digital slide images were acquired at 20× magnification using the
Aperio ScanScope (Vista, CA). From the CD31-stained slides, micro-
vessel density was quantitated using the Aperio (Vista, CA) Micro-
vessel Analysis software; briefly, the software was tuned to detect
and join regions of endothelial staining. The number of vessels de-
tected was divided by the total area of viable tumor to determine
the microvessel density.
Cleaved Parp staining was measured on areas of viable tumor using
the Aperio Color Deconvolution Algorithm, which quantitates pixels
sufficiently stained with chromogen to be counted positive. Ki-67
expression was quantitated on areas of viable tumor using the Aperio
Nuclear Algorithm, which counts nuclei based on counterstain and
then calculates how many are sufficiently stained with chromogen to
be counted positive.
In addition, the Aperio Color Deconvolution Algorithm was used
to generate maps of intracellular and extracellular regions based on
intensity thresholding on H&E-stained sections. A region was drawn
to encompass the entire slice of tumor (AROI), and every pixel was
analyzed to determine whether it contained enough staining to be
counted. Pixels that did not reach the minimum threshold were con-
sidered nonstained (i.e., extracellular regions). Statistics summarizing
the thresholding that include total region area (AROI) and total stained
area (Astain) were used to determine the percentage of extracellular
(EC) space as shown below:
EC %ð Þ = AROI − Astainð Þ
AROI
 
× 100: ½5
Statistical Analysis
To assess group changes in K trans and ve, an ROI was manually
drawn on the center slice for each tumor at each time point. The aver-
age signal intensity was then fit to to obtain parametric values for each
animal at baseline, at day 3, and at day 5. The same ROIs were applied
to the DW data and fit to as described previously. Data analysis as-
sumed that noise contributed only random and not systematic errors.
Before being placed into the appropriate treatment group for analysis,
the integrity of the data was examined by using either muscle tissue
(DCE-MRI) or water phantom data (DW-MRI). Briefly, if the muscle
Figure 4. K trans parametric maps for representative mice from each treatment group. The columns indicate baseline, day 3, and day 5 time
points, whereas each row shows the cediranib (A-C), AZD1480 (D-F), and sham groups (G-I).
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curve did not qualitatively follow characteristics of a rapid wash-in and
wash-out of CA or if physiologically implausible parameters were re-
turned, the injection was deemed unsuccessful and the DCE-MRI data
were not used. Similarly, if the slice used in the DW-MRI comparison
had a phantom ADC value outside the range of 0.003 mm2/s ± 15%
(experimentally derived ADC of free water at approximately body tem-
perature (37 ± 2°C) at 9.4 T) then the tumor ADC data were also not
used. For each treatment group, the average and 95% confidence inter-
vals (1.96 × SD / √n, where n is the number of samples) were com-
puted. The percent change from baseline for each animal was also
computed, and the average and 95% confidence interval were calcu-
lated. A Wilcoxon signed rank test was used to determine significant
differences between each treatment group (both absolute and percent
change data) [25]. Histologic data were quantified using pathologic
scoring and compared with all imaging metrics.
Results
In total, n = 12/n = 10/n = 9mice were imaged at three time points for the
cediranib/AZD1480/sham groups, respectively. Animal data that exhib-
ited a faulty injection (no contrast uptake) or an occluded catheter were
not included in the DCE-MRI group analyses; similarly, animal data
collected for the ADC study that were contaminated by motion (as re-
flected by the water phantom control measurement) were not included
in further analyses. The number of mice used in analyses at each time
point is indicated in Tables 1 to 3. The tumor volume changes for all
animals are shown in Figure 1, where the square/solid line indicates ani-
mals treated with cediranib, the circle/dashed line indicates animals treated
with AZD1480, and the triangle/dashed line represents animals in the
sham group. The vertical lines are the 95% confidence interval for each
respective group. There was no statistically significant difference in tumor
volume among these groups at the measured time points, which is not
unexpected given the relatively short, 5-day duration of drug treatment.
Group Analyses
Three representative DCE-MRI curves (representing each time
point) from a mouse in each treatment group are shown in Figure 2.
The dynamic data and curve fit (in black) were taken from baseline,
whereas the red and blue fit lines indicate days 3 and 5 data, respec-
tively. Figure 2A shows the dramatic effect of cediranib on K trans
Figure 5. ADC parametric maps for a representative mouse from each treatment group. The columns indicate baseline, day 3, and day 5
time points, whereas each row shows the cediranib (A-C), AZD1480 (D-F), and sham groups (G-I).
Neoplasia Vol. 14, No. 1, 2012 DW-MRI and DCE-MRI for AZD1480-Treated Mice Loveless et al. 59
(denoted by the arrow), whereas Figure 2, B and C , shows that K trans
changes very little or without trend (as denoted by the arrows) in the
AZD1480 and sham, respectively.
The results of the percent change in the group analyses are displayed
in Figure 3. Animals treated with the VEGFR inhibitor, cediranib,
showed significant decreases in K trans at both days 3 and 5 with an
average percent difference of −29% and −53%, respectively (Figure 3A).
The average percent differences in the AZD1480 treatment group were
−21% and −23% for each posttreatment time points, whereas the sham
group showed stable decreases of 26% at both subsequent time points.
No significant differences were found in either AZD1480 or sham
groups at either posttreatment time points for K trans. Average absolute
K trans values for these treatment groups are listed in Table 1.
In Figure 3B, the percent change in ADC shows that both treatment
groups demonstrate an increasing trend with a significant increase for
the AZD1480 group at both days 3 (63%) and 5 (49%) after treat-
ment. Whereas the cediranib group shows an increase on day 5 for
ADC, only three animals were available at this final time point so this
subgroup lacks power to achieve statistical significance. Also of note,
the sham group trended negatively, suggesting that the ADC decreased
as the tumor grew. Mean absolute ADC values for these treatment
groups are listed in Table 2.
In Figure 3C , the group changes for ve are given. No significant
changes from baseline in ve were seen with the exception of day 5 of
cediranib treatment, which reflected a significant decrease at this time
point. The absolute values of ve for each treatment group are listed in
Table 3.
Parametric Map Analyses
To further explore the efficacy of K trans, ADC, and ve to report
on these treated animals, parametric maps were constructed. Figure 4
illustrates a panel of K trans maps for each treatment group (rows:
cediranib, AZD1480, and sham) at each time point (columns: base-
line, day 3, and day 5). These maps illustrate a significant decrease in
K trans values for the cediranib treatment group, shown by the arrow
(Figure 4, A, B, and C ), whereas little change or trend is noted in the
AZD1480 group (Figure 4, D, E , and F ). Interestingly, in this sham
animal, higher K trans values are found at the day 5 time point, as shown
by the arrow (Figure 4, G , H , and I).
ADC maps were also constructed and displayed in Figure 5. In a
similar fashion, one representative animal from each treatment group
is displayed in the rows (cediranib, AZD1480, and sham groups),
whereas each column represents the imaging time points (baseline,
day 3, and day 5). The ADC maps do not show a dramatic difference
Figure 6. ve parametric maps for a representative mouse from each treatment group. The columns indicate baseline, day 3, and day 5 time
points, whereas each row shows the cediranib (A-C), AZD1480 (D-F), and sham groups (G-I).
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in this particular cediranib-treated animal (Figure 5, A, B, and C ),
whereas there is an apparent increase in ADC values for this
AZD1480-treated animal (Figure 5, D, E , and F). The sham group
(Figure 5, G , H , and I ) shows a decrease in ADC values that reflect
the group analyses mentioned previously.
The final series of panels, shown in Figure 6, displays ve data from
representative animals from the treatment groups in a similar fashion.
No trends or correlations are evident with this parameter. Interestingly,
this parameter maintains very high values at all time points for all treat-
ments. Some voxels surpassed the physiological boundary (ve = 1),
which were excluded from analyses.
Histologic Correlation
Because Jak kinase is a key regulator of STAT3 phosphorylation,
tumor samples were stained for pSTAT3 2 hours after drug or sham
dosing. As expected, treatment with the VEGFR inhibitor cediranib
showed no effect on pSTAT3 relative to shams (staining detected in
seven of eight and in six of seven tumors, respectively), whereas
pSTAT3 was significantly inhibited after treatment with AZD1480
(staining in 2/11 tumors). Representative images are shown in Figure 9.
To histologically assess vascularity, samples were stained for the
endothelial cell marker CD31. As shown in Figure 7, no significant
changes in microvessel density could be detected by CD31 staining in
these samples owing to the large variation within the sham group.
However, a trend toward reduction of microvessel density could be dis-
cerned in AZD1480-treated samples and more markedly in cediranib-
treated samples.
Additional immunohistochemistry analyses for cellular activity
included H&E, Ki-67, and cParp staining; the results of these anal-
yses are shown in Figure 8. Figure 8A demonstrated the extracellular
space fraction (EC (%)) on H&E-stained slides, calculated as de-
scribed in the Materials and Methods section, for each group. A signif-
icant (P < .05) increase in EC (%) was found between the AZD1480
treatment group and the sham group, whereas the cediranib-treated
group was indistinguishable from the sham group. Ki-67 was used to
identify the percentage of cells that were proliferating at the last imaging
time point; the results for all three groups are shown in Figure 8B, and
no statistical significance was reported between treatment and sham
groups. Finally, apoptotic activity was quantified as the percentage of
cells that stained positive for cParp, a marker of apoptosis. The results of
this study are shown in Figure 8C with a statistically significant (P =
.036) increase in cParp staining for the AZD1480 treatment group
compared with the sham group. Examples of staining for CD31, Ki-67,
and cParp are shown in Figure 9.
Discussion
STAT3 has been shown to promote tumor development through the
activation of several oncogenic pathways, including cell proliferation,
survival, and tumor angiogenesis. Jak kinase has been shown to play a
central role in STAT3 activation in solid tumor cell lines [7,26–30],
and inhibition of Jak1/2 with AZD1480 has been demonstrated
to abrogate STAT3 phosphorylation and inhibit tumor xenograft
growth [7]. One of the unique advantages of imaging tumor physi-
ology is the ability to capture changes before any palpable/volumetric
changes in tumor growth. Thus, the goal of this study was to exam-
ine the sensitivity of two imaging techniques to the antiangiogenic
and antitumorigenic activity of AZD1480.
Figure 7.Mean microvessel density calculated from CD31 staining
in each treatment group. Bars, SD.
Figure 8. (A, B, and C) Cell density, Ki-67, and cParp staining re-
sults, respectively, for each group. Each “•” represents a sample
with the bold solid line being the mean and the error bars above
and below indicate the 95% confidence interval. (A) Cell density
results as determined by H&E staining. (B) Percentage of nuclei
that stained positive for Ki-67 activity. (C) Percentage of cParp-
positive pixels.
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In this study, no significant change in K trans was noted in the
AZD1480 group at any postdosing time points. However, there
was a significant decrease in K trans for mice treated with the VEGFR
inhibitor cediranib. Histologic analysis of tumor tissue stained with the
endothelial cell marker CD31 did not reveal any significant changes in
tumors treated with cediranib and AZD1480 relative to shams; how-
ever, significant variability in sham staining in these studies may have
obscured treatment responses. Significant inhibition of vascularity has
been detected in this xenograft tumor model after 6 days of treatment
with AZD1480 in another study [31]. Thus, K trans does not seem to
be sensitive enough to detect the changes in microvasculature for
AZD1480-treated tumors after 5 days of treatment; alternatively, a
reduced number of animals for the AZD1480 group on day 5 (n = 5)
may have been too small to definitely detect a change in K trans from
baseline measurements. ADC provided a more sensitive measure for
the response to AZD1480 treatment at early time points. Significant
increases in ADC were indicated in the group study and shifts were
noted on a voxel-by-voxel level. In addition, although changes in tumor
volume gave no significant indications of efficacy for this group, there
was a significant increase in apoptosis and extracellular space (EC (%))
in this treatment group.
DW-MRI has previously been shown to correlate with cell density
measures in cancer [32–35]. In this study, significant difference was
found in extracellular space (indirectly identifying cell density) mea-
sures from H&E in the AZD1480 group; however, ve did not illustrate
any significant trends other than demonstrating a significant decrease
on day 5 for the cediranib-treated group. As cells die because of treat-
ment, ve should, in theory, increase; however, previous studies have
shown that ve has not consistently exhibited this behavior and is depen-
dent on treatment as well as the DCE-MRI model used [17,36]. In
some cases, ve reached an unphysical value (ve > 1); these voxels were
excluded from further statistical analyses. The sources of error in ve
could have arisen from slowly enhancing voxels in poorly perfused areas
that may rely on passive diffusion for transportation of the contrast
agent. In addution, the use of a population VIF can lead to parameter
errors due to overestimating or underestimating the Cp in individual
subjects. Recognizing this as a limitation of the study, we eliminated
those voxels as including them would have skewed both ve and K
trans
Figure 9. Sample staining for pSTAT3 (first row), CD31 (second row), Ki-67 (third row), and cParp (last row) for sham group (first column),
the cediranib treatment group (second column), and the AZD1480 treatment group (last column). There is clear evidence that pSTAT3 in
AZD1480 is suppressed in treated animals (no brown staining). The brown staining shown in the CD31 staining indicates a positive stain
for CD31 on endothelial cells, whereas a brown staining in the Ki-67 images indicates cells that are in a proliferative state. The brown
staining for the cParp images indicate cells positive for the Parp cleavage typically characterized by cells undergoing apoptosis.
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measurements. With a significant increase in cleaved Parp, indicative of
caspase 3–dependent apoptosis [30], and EC (%) and no difference in
Ki-67 (proliferation marker), one could hypothesize that the changes in
ADC are primarily induced by proapoptotic activity. As cells die, the
extracellular space increases so the ADC increases.
ADC can be affected by several cellular/extracellular processes such
as changes in active transport, blood flow, and tissue organization
[9]. These changes can also be transient with treatment activity;
for example, initial cellular swelling and reduced blood flow may lead
to lower ADC values earlier in treatment [37]. As cells begin to die,
edema, reduced cell density, and tissue reorganization may lead to an
increase in ADC, as seen frequently during treatment of malignant
tumors [9]. Thus, it is possible that the change in ADC reflects a
change in tissue environment as apoptosis increases. Whereas no sig-
nificant changes in ADC were noted in the cediranib group (n = 3),
the ADC at day 5 demonstrated an increasing trend as did the percent
extracellular space (EC (%)).
Conclusions
The goal of this study was to assess the sensitivity of DCE-MRI and
DW-MRI biomarkers to the antiangiogenic and antitumorigenic
activity of AZD1480. As anticipated, K trans, an indicator of blood
flow/perfusion reported significant changes from baseline for the
antiangiogenic drug, cediranib, treatment group; this finding was also
supported by histology. K trans did not reliably report any treatment
response for AZD1480, although histologic analysis showed a general
decrease in microvessel density, but significant changes in ADC were
measured at both days 3 and 5 after treatment, consistent with path-
ologic detection of significant apoptotic activity and increased extra-
cellular fraction. Measurements of diffusion may provide a useful
biomarker for early treatment response to a Jak1/2 inhibitor.
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